Ganaxolone for Treatment in Epilepsy
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit
Updated: 06/24/2019
Pipeline Type
New Drugs in Development
Phase Of Development
Phase 3
Sponsors and Collaborators
Marinus Pharmaceuticals, Epilepsy Foundation (EF)
Mechanism of Action
Mechanism Description
synthetic analog of endogenous allopregnanolone which modulats GABAa Receptors
Populations Tested In
PCDH19-related epilepsy ages 1 to 17; CDKL5 ages 2 to 21
Other Resources
Special FDA Designation
Nonprofit or Government Support
Nonprofit
Nonprofit or Government Support Description
Epilepsy Foundation - 2005 investment
Previous Presentations
Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
AEDD XV - May 2019
Location of Clinical Trials
N/A